In the studies using the higher weight-loss doses, this risk approximately doubled compared to placebo
Drugmakers are also making significant headway in developing and releasing generic versions of GLP-1 medications, with the FDA approving the first 2 generic GLP-1 drugs in November and December 2024, respectively, although neither of those drugs has weight-loss-specific uses
[13] [1] Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disease affecting the central nervous system, characterized by demyelination, axonal damage, and progressive neurological disability
16 Owing to the unique mechanism by which SNAC facilitates absorption of semaglutide within the stomach, it is important to consider the impact of meals on drug absorption
Dietary compounds such as flavonoids and isothiocyanates can stimulate the Nrf2 pathway, leading to the expression of various antioxidant enzymes and detoxifying proteins 12,13,14